Patents for A61P 35 - Antineoplastic agents (221,099)
01/2008
01/17/2008US20080015177 S1P receptor modulating compounds and use thereof
01/17/2008US20080015176 such as dabigatran etexilate in children; congenital heart disease, shunt or catheter thrombosis, pulmonary embolism, stroke in pregnant girls; pediatrics
01/17/2008US20080015175 Nontoxic; inhibition of interleukin-1 beta -converting enzyme
01/17/2008US20080015173 Estrogen Receptor Modulators
01/17/2008US20080015172 Caspase inhibitors and uses thereof
01/17/2008US20080015169 Amino-methyl substituted tetracycline compounds
01/17/2008US20080015165 Novel polypeptide
01/17/2008US20080015157 Novel Water-Soluble Prodrugs
01/17/2008US20080015153 Pharmaceutical compositions containing the long pentraxin PTX3
01/17/2008US20080015152 Therapeutic amino acid sequences for use in treatment and prevention of viral, infectious, cancerous, diabetic, incontinent, hypertensive, eating and nervous system disorders
01/17/2008US20080015150 Peptides and Derivatives Thereof Showing Cell Attachment, Spreading and Detachment Activity
01/17/2008US20080015149 Galectin 11
01/17/2008US20080015146 e.g. 3-Amino-1-[(S)-2-(3-tert-butyl-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-4-(2,4,5-trifluorophenyl)-butan-1-one; dipeptidyl-peptidase inhibitor; antidiabetic, hypoglycemic agent; metabolic disorders, obesity, non-insulin dependent diabetes
01/17/2008US20080015143 In Vitro Methods for Detecting Renal Cancer
01/17/2008US20080014577 Oncolytic viruses as phenotyping agents for neoplasms
01/17/2008US20080014255 Liposome bonded with antibody and polyalkylene glycol
01/17/2008US20080014253 Lipid-Based Drug Delivery Systems Containing Unnatural Phospholipase A2 Degradable Lipid Derivatives and the Therapeutic Uses Thereof
01/17/2008US20080014252 Topical compositions with long lasting effect
01/17/2008US20080014249 Compositions and therapeutic methods involving isoflavones and analogues thereof
01/17/2008US20080014248 Photosensitizer containing indole-3-alkylcarboxylic acid, and kit for photodynamic therapy containing the same
01/17/2008US20080014246 Methods and compounds for controlled release of recombinant parvovirus vectors
01/17/2008US20080014238 Implantable medical devices comprising semi-crystalline poly(easter-amide)
01/17/2008US20080014237 Sustained release compositions, process for producing the same and use thereof
01/17/2008US20080014227 Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
01/17/2008US20080014222 Cancer immunotherapy compositions and methods of use
01/17/2008US20080014210 Peptides and antibodies to muc 1 proteins
01/17/2008US20080014208 Fusion proteins, uses thereof and processes for producing same
01/17/2008US20080014207 Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents
01/17/2008US20080014203 Immunoglobulin which binds insulin-like growth factor receptor (IGF-IR ) for use in diagnosis, prevention and treatment of cell proliferative disorders; antitumor agents
01/17/2008US20080014200 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
01/17/2008US20080014199 Assessing Cancer And Vimentin
01/17/2008US20080014198 Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels
01/17/2008US20080014197 Neutralizing human anti-igfr antibody
01/17/2008US20080014196 Compositions and methods for modulating vascular development
01/17/2008US20080014190 Proteinases destroy cancer tumor's solid structure and kill cancer cells locally
01/17/2008US20080014189 Diaminotriazoles useful as inhibitors of protein kinases
01/17/2008US20080014186 Hla-A24 or Hla-A2 Binding Peptides of Parathyroid Hormone-Related Protein
01/17/2008US20080014175 Methods and Compositions for Viral Enhancement of Cell Killing
01/17/2008US20080014174 Method for treating tumors, infectious diseases, and autoimmune diseases with an activated HLA matching donor-originating lymphocyte
01/17/2008DE102006032424A1 Behandlung von T-Zell-Malignomen Treatment of T-cell malignancies
01/17/2008DE102006031224A1 New sulfoximine-substituted pyrimidines useful for treating e.g. diseases caused by inflammatory, allergic or proliferative processes, oncological diseases, cancer, eye, autoimmune and neurodegerative diseases
01/17/2008CA2659590A1 Irreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof
01/17/2008CA2658223A1 Benzopyranopyrazoles
01/17/2008CA2658222A1 Methods and compositions for increasing the efficiency of therapeutic antibodies using .gamma. .delta. t cell activators
01/17/2008CA2658146A1 Crystalline nemorubicin hydrochloride
01/17/2008CA2657816A1 Tetrahydrofuro [3, 2 -b] pyrr0l-3-ones as cathepsin k inhibitors
01/17/2008CA2657385A1 Cell death inducer
01/17/2008CA2657381A1 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhibitors
01/17/2008CA2657375A1 Combination methods of treating cancer
01/17/2008CA2657336A1 Substituted isoxalines, pharmaceutical compositions containing same, methods of preparing same, and uses of same
01/17/2008CA2657327A1 Fused heterocyclic derivatives and methods of use
01/17/2008CA2657308A1 Treatment of excessive neovascularization
01/17/2008CA2657133A1 Anti-human .alpha.9 integrin antibody and use of the same
01/17/2008CA2657062A1 Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
01/17/2008CA2656836A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy
01/17/2008CA2655750A1 2-arylindole derivatives as mpges-1 inhibitors
01/17/2008CA2654583A1 Mtki quinazoline derivatives
01/17/2008CA2635903A1 Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity
01/16/2008EP1878749A2 Individulized anti-cancer antibodies
01/16/2008EP1878748A2 Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 costimulatory antigens
01/16/2008EP1878746A2 Human monoclonal antibodies to epidermal growth factor receptor
01/16/2008EP1878730A1 Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
01/16/2008EP1878726A1 Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
01/16/2008EP1878442A1 Method for treating body fluid
01/16/2008EP1878440A1 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
01/16/2008EP1878438A2 Ligand/llytic peptide compositions and methods of use
01/16/2008EP1878437A2 Pharmacuetical formulations for sustained drug delivery
01/16/2008EP1877559A1 Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
01/16/2008EP1877434A2 Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
01/16/2008EP1877428A2 Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
01/16/2008EP1877424A1 Inhibitors of protein kinases and uses thereof
01/16/2008EP1877423A2 Htm4 used for cell-cycle regulation through its interaction with kap
01/16/2008EP1877419A2 Polymorphic and amorphous salt forms of squalamine dilactate
01/16/2008EP1877409A2 Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
01/16/2008EP1877406A1 New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
01/16/2008EP1877398A1 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors
01/16/2008EP1877397A1 Quinazoline derivatives as inhibitors of egf and/or erbb2 receptor tyrosine kinase
01/16/2008EP1877383A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity
01/16/2008EP1877366A1 Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity
01/16/2008EP1877141A2 Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
01/16/2008EP1877097A2 Aminoacid conjugates of beta-lapachone for tumor targeting
01/16/2008EP1877070A2 Dosage of oligonucleotides
01/16/2008EP1877069A2 Novel use of spiegelmers
01/16/2008EP1877048A1 Combination cancer therapy with bis(thiohydrazide) amide compounds
01/16/2008EP1877044A2 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
01/16/2008EP1877043A1 Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization
01/16/2008EP1532154B1 Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
01/16/2008EP1492793B1 New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives
01/16/2008EP1399188B1 Perylenequinones for use as sonosensitizers
01/16/2008EP1392306B1 Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
01/16/2008EP1326894B1 Novel tumor-associated marker
01/16/2008EP1322656B1 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
01/16/2008EP1317432B1 Piperidine derivatives for use as 2,3-oxidosqualene-lanosterol cyclase inhibitors
01/16/2008EP1279039B1 Diagnostic assay involving macrophage inhibitory cytokine -1 (mic-1)
01/16/2008EP1261694B1 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
01/16/2008EP1204626B1 Ether compounds, compositions, and uses thereof
01/16/2008EP1198255B1 Identification of compounds that modify transcriptional responses to hypoxia
01/16/2008EP1173480B1 Stereoselective antifibrillogenic peptides
01/16/2008EP1122242B1 Cyanophenyl derivatives
01/16/2008EP1107969B1 Collections of compounds